Clinical Trial Update: Anti-IL-17 a New Treatment for Contact Dermatititis [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update evaluating an anti-IL-17A agent for allergic contact dermatitis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Allergic Contact Dermatitis

Drugs mentioned

• Anti-IL-17A inhibitor

Snippet

Sponsor: Tanja Todberg, MD | Conditions: Allergic Contact Dermatitits | Phase 3 | Status: UNKNOWN